Therapy Development for Diffuse Large B-cell Lymphoma in its Limited Stage

The most prevalent Non-Hodgkin Lymphoma (NHL) is Diffuse Large B-Cell Lymphoma (DLBCL), with limited-stage DLBCL being classified as stage I or stage II illness. Advanced-stage DLBCL differs from early-stage DLBCL in risk classification, initial treatment options, and recurrence patterns, however there is little information on the influence of biologic characteristics on outcome. Patients achieve outstanding results, with a 2-year survival rate of almost 90%. Sequential prospective trials and sizable registry studies have assessed the ideal number of chemotherapy cycles and applied PET-adapted strategies to lessen the requirement for radiotherapy during the past few years. Bulky disease, extra nodal disease, totally resected situations, and unfavorable biologic characteristics including high-grade B-cell lymphoma with double/triple hit rearrangements still require special attention.